Recent Findings in Breast Cancer Described by Researchers from University of Florida (Cost-effectiveness of Early Vs Delayed Use of Abemaciclib Combination Therapy for Patients With High-risk Hormone Receptor-positive/ Human Epidermal Growth...).

Researchers from the University of Florida conducted a study comparing the cost-effectiveness of early versus delayed use of abemaciclib combination therapy for patients with high-risk hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer. The study found that early use of abemaciclib was more cost-effective, yielding more life-years and quality-adjusted life-years compared to delayed use. The research suggests that administering abemaciclib in the early stage of the disease is a cost-effective strategy. [Extracted from the article]